Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
FLT3 length mutation (FLT3-LM) is a molecular marker potentially useful for the characterization of acute myeloid leukemia (AML). To evaluate the distribution of FLT3-LM within biologic subgroups, we screened 1003 patients with AML at diagnosis for this mutation. FLT3-LM was found in 234 (23.5%) of all patients and thus is the most frequent mutation in AML described so far. Of all positive patients, 165 (70.5%) revealed a normal karyotype. Of the 69 patients with chromosome aberrations, 24 (34.8%) had a t(15;17). The mutation was rare in AML with t(8;21), inv(16) 11q23 rearrangements, and complex karyotypes. FLT3-LM was not distributed equally within different French-American-British (FAB) subtypes and was correlated with a high peripheral blood count in FAB M1, M2, and M4 (P < .0001). In addition, the median age of patients with the mutation was lower (54.9 vs 57.6 years;P = .043), and, at a ratio of 1.36:1 (P = .023), the mutation was more frequent in females than in males. Within the AMLCG study, FLT3-LM was of intermediate prognostic significance. The complete remission rate of 70.3% in patients with FLT3-LM was similar to that (70.4%) in patients without FLT3-LM. Overall survival was not different between patients with or without FLT3-LM. In contrast, patients with FLT3-LM had a significantly shorter event-free survival (7.4 vs 12.6 months;P = .0072) because of a higher relapse rate. Besides the importance of FLT3-LM for biologic and clinical characterization of AML, we show its value as a marker for disease monitoring based on 120 follow-up samples of 34 patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
A simple salting out procedure for extracting DNA from human nucleated cells
Miller, S. A., Dykes, D. D., & Polesky, H. F. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.3.1215 · Cited by 20,330
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K., Vardiman, J., Lister, T. A., & Bloomfield, C. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3835 · Cited by 3,267
BENNETT, J. M., CATOVSKY, D., DANIEL, M. T., FLANDRIN, G., GALTON, D. A. G., GRALNICK, H. R., & SULTAN, C. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-4-620 · Cited by 2,926
Oncogenic Transcription Factors in the Human Acute Leukemias
Look, A. T. (1997) · Science · doi:10.1126/science.278.5340.1059 · Cited by 1,187
Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.
Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T., & Misawa, S. (1996) · PubMed · Cited by 1,162
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Yamamoto, Y. (2001) · Blood · doi:10.1182/blood.v97.8.2434 · Cited by 1,150
Pabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G. (2001) · Nature Genetics · doi:10.1038/85820 · Cited by 901
Self-citationHarris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K., Vardiman, J., Lister, T. A., & Bloomfield, C. D. (1999) · Annals of Oncology · doi:10.1023/a:1008375931236 · Cited by 846
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., et al. (1999) · PubMed · doi:10.1182/blood.v93.9.3074 · Cited by 757
Whitman, S. P., Archer, K. J., Lin, F., Baldus, C. D., Becknell, B., Carlson, B. D., Carroll, A. J., Mrózek, K., Vardiman, J., George, S. L., et al. (2001) · PubMed · Cited by 710
Mizuki, M., Fenski, R., Halfter, H., Matsumura, I., Schmidt, R., Müller, C., Grüning, W., Kratz-Albers, K., Serve, S., Steur, C., et al. (2000) · Blood · doi:10.1182/blood.v96.12.3907 · Cited by 606
Self-citationMeshinchi, S., Woods, W. G., Stirewalt, D. L., Sweetser, D. A., Buckley, J. D., Tjoa, T. K., Bernstein, I. D., & Radich, J. P. (2001) · Blood · doi:10.1182/blood.v97.1.89 · Cited by 518
Yokota, S., Kiyoi, H., Nakao, M., Iwai, T., Misawa, S., Okuda, T., Sonoda, Y., Abe, T., Kahsima, K., Matsuo, Y., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400812 · Cited by 455
Kiyoi, H., Towatari, M., Yokota, S., Hamaguchi, M., Ohno, R., Saito, H., & Naoe, T. (1998) · Leukemia · doi:10.1038/sj.leu.2401130 · Cited by 453
Osato, M., Asou, N., Abdalla, E., Hoshino, K., Yamasaki, H., Okubo, T., Suzushima, H., Takatsuki, K., Kanno, T., Shigesada, K., et al. (1999) · Blood · doi:10.1182/blood.v93.6.1817.406k36_1817_1824 · Cited by 397
Identification of novel FLT‐3 Asp835 mutations in adult acute myeloid leukaemia
Abu‐Duhier, F. M., Goodeve, A. C., Wilson, G. A., Care, R. S., Peake, I. R., & Reilly, J. T. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02850.x · Cited by 388
Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia
Kiyoi, H., Naoe, T., Yokota, S., Nakao, M., Minami, S., Kuriyama, K., Takeshita, A., Saito, K., Hasegawa, S., Shimodaira, S., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400756 · Cited by 344
FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group
Abu-Duhier, F. M., Goodeve, A. C., Wilson, G. A., Gari, M. A., Peake, I. R., Rees, D. C., Vandenberghe, E. A., Winship, P. R., & Reilly, J. T. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02317.x · Cited by 310
C-kit mutations in core binding factor leukemias
Beghini, A., Peterlongo, P., Ripamonti, C. B., Larizza, L., Cairoli, R., Morra, E., & Mecucci, C. (2000) · Blood · doi:10.1182/blood.v95.2.726 · Cited by 299
Rombouts, W., Blokland, I., Löwenberg, B., & Ploemacher, R. (2000) · Leukemia · doi:10.1038/sj.leu.2401731 · Cited by 277
Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics.
Caligiuri, M. A., Strout, M. P., Lawrence, D. D., Arthur, D., Baer, M., Yu, F., Knuutila, S., Mrózek, K., Oberkircher, A. R., Marcucci, G., et al. (1998) · PubMed · Cited by 224
Horiike, S., Yokota, S., Nakao, M., Iwai, T., Sasai, Y., Kaneko, H., Taniwaki, M., Kashima, K., Fujii, H., Abe, T., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400770 · Cited by 209
Tse, K.-F., Mukherjee, G., & Small, D. (2000) · Leukemia · doi:10.1038/sj.leu.2401905 · Cited by 195
Caligiuri, M. A., Strout, M. P., Schichman, S. A., Mrózek, K., Arthur, D., Herzig, G. P., Baer, M., Schiffer, C. A., Heinonen, K., Knuutila, S., et al. (1996) · PubMed · Cited by 185
Xu, F., Taki, T., Yang, H. W., Hanada, R., Hongo, T., Ohnishi, H., Kobayashi, M., Bessho, F., Yanagisawa, M., & Hayashi, Y. (1999) · British Journal of Haematology · doi:10.1111/j.1365-2141.1999.01284.x · Cited by 178
Johansson, B., Mertens, F., & Mitelman, F. (1996) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199607)16:3<155::aid-gcc1>3.0.co;2-y · Cited by 169
Schichman, S. A., Caligiuri, M. A., Strout, M. P., Carter, S. L., Gu, Y., Canaani, E., Bloomfield, C. D., & Croce, C. M. (1994) · PubMed · Cited by 165
Lengfelder, E., Reichert, A., Schoch, C., Haase, D., Haferlach, T., Löffler, H., Staib, P., Heyll, A., Seifarth, W., Saussele, S., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401843 · Cited by 162
Self-citationPrognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group
Bradstock, K. F., Matthews, J., Benson, E. M., Page, F., & Bishop, J. F. (1994) · Blood · doi:10.1182/blood.v84.4.1220.1220 · Cited by 161
Lisovsky, M. Y., Estrov, Z. E., Zhang, X., Consoli, U., Sanchez‐Williams, G., Snell, V., Munker, R., Goodacre, A., Vg, S., & Andreeff, M. (1996) · Blood · doi:10.1182/blood.v88.10.3987.bloodjournal88103987 · Cited by 151
Fenski, Flesch, Serve, Mizuki, Oelmann, Kratz‐Albers, Kienast, Leo, Schwartz, Berdel, et al. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.01831.x · Cited by 146
Nakano, Y., Kiyoi, H., Miyawaki, S., Asou, N., Ohno, R., Saito, H., & Naoe, T. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01256.x · Cited by 110
Poirel, H. A., Rack, K. A., Delabesse, É., Radford‐Weiss, I., Troussard, X., Debert, C., Leboeuf, D., Bastard, C., Picard, F., Buzyn, A., et al. (1996) · Blood · doi:10.1182/blood.v87.6.2496.bloodjournal8762496 · Cited by 96
Secondary chromosomal abnormalities in acute leukemias.
Johansson, B., Mertens, F., & Mitelman, F. (1994) · PubMed · Cited by 94
Molecular biology of acute myeloid leukemia.
Caligiuri, M. A., Strout, M. P., & Gilliland, D. G. (1997) · PubMed · Cited by 91
Motor performance of children during treatment for acute lymphoblastic leukemia
Reinders‐Messelink, H. A., Schoemaker, M. M., Snijders, T. A. B., G�eken, L., van den Briel, M. M., B�kkerink, J. P. M., & Kamps, W. A. (1999) · Medical and Pediatric Oncology · doi:10.1002/(sici)1096-911x(199912)33:6<525::aid-mpo1>3.0.co;2-8 · Cited by 88
In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor
Zhao, M., Kiyoi, H., Yamamoto, Y., Ito, M. A., Towatari, M., Ōmura, S., Kitamura, T., Ueda, R., Saito, H., & Naoe, T. (2000) · Leukemia · doi:10.1038/sj.leu.2401680 · Cited by 79
Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse
Garson, O. M., Hagemeijer, A., SAKURAI, M., Reeves, B. R., Swansbury, G. J., Williams, G. J., Alimena, G., Arthur, D., Berger, R., de la Chapelle, A., et al. (1989) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(89)90024-1 · Cited by 65
Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia.
Estey, E. H., Keating, M. J., Pierce, S. A., & Stass, S. A. (1995) · PubMed · Cited by 60
Cited by
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Kottaridis, P. D., Gale, R. E., Frew, M. E., Harrison, G., Langabeer, S. E., Belton, A. A., Walker, H., Wheatley, K., Bowen, D. T., Burnett, A. K., et al. (2001) · Blood · doi:10.1182/blood.v98.6.1752 · Cited by 1,551
The role of FLT3 in haematopoietic malignancies
Stirewalt, D. L., & Radich, J. P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1169 · Cited by 865
Gale, R. E., Green, C., Allen, C., Mead, A. J., Burnett, A. K., Hills, R. K., & Linch, D. C. (2008) · Blood · doi:10.1182/blood-2007-08-109090 · Cited by 745
Metadata
- Authors
- Schnittger, S., Schoch, C., Dugas, M., Kern, W., Staib, P., Wuchter, C., Löffler, H., Sauerland, C. M., Serve, H., Büchner, T., Haferlach, T., & Hiddemann, W.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2002-07-01
- Volume
- 100
- Issue
- 1
- Pages
- 59-66
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2150470057
- Cited by
- 973
- References
- 42
- FWCI
- 28.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.